Intraventricular Hemorrhage clinical trials at UC Cancer

• A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature Infants

  open to all eligible people

  The purpose of this study is to determine if an investigational drug can reduce the burden of chronic lung disease in extremely premature babies through 12 months corrected age (CA), as compared to extremely premature babies receiving standard neonatal care alone.

  at UCLA

Last updated: January 7, 2021